Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | P4HB | P07237 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203965 | 1.00 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17985114 | 0.85 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17985115 | 0.85 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16621084 | 0.84 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16621083 | 0.84 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14127518 | 0.84 | GABRG2 (0.49) | CA1CA2CA9PTGS2PTGS1 | |
| SCHEMBL2909491 | 0.80 | PTGS2 (0.53) | P4HBCA1CA2CA9CA7 | |
| SCHEMBL3198697 | 0.80 | PTGS2 (0.53) | P4HBCA1CA2CA9CA7 | |
| SCHEMBL3190840 | 0.80 | PTGS2 (0.53) | P4HBCA1CA2CA9CA7 | |
| SCHEMBL3190836 | 0.80 | PTGS2 (0.53) | P4HBCA1CA2CA9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| US-7674773-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7576200-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7488829-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20080281092-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2008-11-13 | — | — | US | disclosed |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2007-09-06 | — | — | US | disclosed |
| EP-1345895-B1 | NOVEL 1,2-DIPHENZYLAZETIDINONES, METHOD FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF FOR TREATING DISORDERS OF THE LIPID METABOLISM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-6992067-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-12-01 | — | — | US | disclosed |
| EP-1345895-A1 | NOVEL 1,2-DIPHENZYLAZETIDINONES, METHOD FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF FOR TREATING DISORDERS OF THE LIPID METABOLISM | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-26 | — | — | US | disclosed |
| WO-2002050027-A1 | NOVEL 1,2-DIPHENZYLAZETIDINONES, METHOD FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF FOR TREATING DISORDERS OF THE LIPID METABOLISM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281092-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | GRIN2D 2875/4885GRIN3B 4013/4885GRIN1 2888/4885 |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB7, NDUFB6 | GRIN2D 3028/4885GRIN3B 4110/4885GRIN1 2385/4885 |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | GRIN2D 2875/4885GRIN3B 4013/4885GRIN1 2888/4885 |
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | QDPR, NDUFB6, NDUFB7 | GRIN2D 2875/4885GRIN3B 4013/4885GRIN1 2888/4885 |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | GRIN2D 2875/4885GRIN3B 4013/4885GRIN1 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.